Literature DB >> 6447181

Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties.

B M Alving, D L Tankersley, B L Mason, F Rossi, D L Aronson, J S Finlayson.   

Abstract

The intramuscular or intravenous administration of ISG prepared from human plasma by ethanol fractionation can elicit such reactions as pain at the injection site, flushing, and even hypotension. Similar adverse reactions to plasma protein fraction, a volume expander also made by ethanol fractionation, have been associated with PKA (Hageman factor fragments) in the product. Twenty-five lots of commercial ISG were therefore analyzed for PKA and kallikrein, components of the contact activation system which could mediate such reactions through the generation of kinins in recipients. Kallikrein activity ranged from undetectable levels to > 60% of the total potential kallikrein activity in normal plasma. PKA, which was measured by its ability to catalyze the conversion of prekallikrein to kallikrein, ranged from 5% to 3950% of the activity in a reference plasma protein fraction that had caused hypotension. All but five lots increased vascular permeability in the guinea pig. The five lots which caused no increased were also the lowest in PKA and kallikrein activity. When ISG ws subjected to gel chromatography to separate the enzymic contaminants from immunoglobulin G, only the fractions containing PKA and/or kallikrein increased vascular permeability. Several lots of ISG shortened the nonactivated partial thromboplastin time of normal plasma fro 236 sec to 38 to 55 sec. During gel chromatography, coagulation activity was eluted in a position corresponding to a molecular weight of 150,000; it was inhibited by antibody to human factor XI. These data indicate that factor XIa is responsible for the coagulant activity observed and that PKA and/or kallikrein are potential mediators of vasoactive reactions to ISG.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6447181

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Assessment of biological activity of immunoglobulin preparations by using opsonized micro-organisms to stimulate neutrophil chemiluminescence.

Authors:  C S Munro; P J Stanley; P J Cole
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

2.  Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model.

Authors:  W K Bleeker; J Agterberg; G Rigter; N van Rooijen; J C Bakker
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

3.  Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.

Authors:  Thierry Burnouf; Birgit Gathof; Evan M Bloch; Renée Bazin; Vincenzo de Angelis; Gopal Kumar Patidar; Rada M Grubovic Rastvorceva; Adaeze Oreh; Ruchika Goel; Naomi Rahimi-Levene; Salwa Hindawi; Arwa Z Al-Riyami; Cynthia So-Osman
Journal:  Transfus Med Rev       Date:  2022-06-09

4.  Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function).

Authors:  B Jenei; G Lázár; K Bartha; G A Medgyesi
Journal:  Agents Actions       Date:  1991-03

Review 5.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

6.  Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity.

Authors:  Josephine H Cheng; Yu-Wen Wu; Chen-Yun Wang; Sharon S Wu; Cheum L Hong; Karen W Chan; Leo X Liao; Xisheng Cao; Bin Wang; Thierry Burnouf
Journal:  Blood Transfus       Date:  2021-08-04       Impact factor: 3.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.